Indication

Hyperfibrinolysis-induced hemorrhage

Hyperfibrinolysis-induced hemorrhage is a severe bleeding complication within the vascular and hematologic systems caused by pathological acceleration of clot breakdown. Read more about Hyperfibrinolysis-induced hemorrhage

24 drugs 22 manufacturers

Advertisement

Drugs that treat it

Common Hyperfibrinolysis-induced hemorrhage therapies.

Showing 1–9 of 24 drugs

AMINOCAPROIC ACID

AMINOCAPROIC ACID·HYPERFIBRINOLYSIS-INDUCED HEMORRHAGE·+1
VITRUVIAS THERA
Filter & compare in the drug finder →Opens the drug finder with Hyperfibrinolysis-induced hemorrhage preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hyperfibrinolysis-induced hemorrhage.

Hyperfibrinolysis-induced hemorrhage is a severe bleeding complication within the vascular and hematologic systems caused by pathological acceleration of clot breakdown.

It commonly arises in acquired clinical settings such as major trauma, cardiopulmonary bypass, liver failure, and acute promyelocytic leukemia, but can also occur from rare congenital deficiencies in fibrinolytic inhibitors.

Pathophysiologically, an excess of plasminogen activators or a deficiency of inhibitors like alpha-2-antiplasmin drives unregulated generation of plasmin, precipitating premature lysis of hemostatic fibrin plugs, consumption of fibrinogen, and accumulation of fibrin degradation products that further impair platelet aggregation and coagulation.

Personalize your experience

Follow Hyperfibrinolysis-induced hemorrhage and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it